Jenburkt Pharma Q1 FY27 Results: Revenue Rs 35 Cr, PAT Rs 5.00 Cr and Key Highlights

August 7, 2026
Posted by: Ankit Jaiswal
Category: News

Jenburkt Pharma Q1 FY27 results declared Aug 6, 2026. Revenue Rs 35 Cr (-0.04% YoY). PAT Rs 5.00 Cr (-24.46% YoY). CMP Rs 1135.65 (-2.03%).

Jenburkt Pharma Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. Jenburkt Pharma Q1 FY27 results show revenue declined -0.04% year-on-year to Rs 35 Cr from Rs 35 Cr in Q1 FY26, reflecting near-term headwinds in the Pharmaceuticals space. The broader Nifty Pharma index also reflected mixed sentiment during the quarter.

Operating profit contracted -34.59% YoY to Rs 5 Cr from Rs 8 Cr, reflecting margin pressure from input costs and competitive dynamics. PAT fell -24.46% YoY to Rs 5.00 Cr from Rs 7.00 Cr in Q1 FY26. The quarterly numbers offer a detailed picture of how the company is navigating the current pharmaceuticals environment.

Click Here – Get Free Investment Predictions

Table of Contents

Jenburkt Pharma Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Jenburkt Pharma Revenue	35	35	-0.04%
Operating Profit	5	8	-34.59%
Net Profit (PAT)	5.00	7.00	-24.46%
Reporting Basis	Standalone

Jenburkt Pharma Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Jenburkt Pharma Q1 FY27 results reflect pressure fundamentals across key financial parameters. Revenue momentum faced near-term headwinds with the top line reaching Rs 35 Cr for the April to June 2026 quarter.

Operating profit stood at Rs 5 Cr, contracting -34.59% YoY. Management is implementing cost reduction measures to restore operating leverage.

PAT of Rs 5.00 Cr marks a -24.46% year-on-year improvement. Investors monitoring Jenburkt Pharma Q1 FY27 results will note this as a key milestone for FY27 tracking.

Key Business Factors in Jenburkt Pharma Q1 FY27 Results

Revenue Normalisation After Prior Year Headwinds

Jenburkt Pharma Q1 FY27 results reflect near-term revenue moderation of -0.04% YoY, attributed to market-specific factors including demand normalisation and channel inventory adjustments.

Operating Profit Under Pressure from Cost Headwinds

Operating profit in Jenburkt Pharma Q1 FY27 results came in at Rs 5 Cr (-34.59% YoY), weighed down by input cost inflation, employee expenses, and competitive pricing dynamics.

PAT Performance and Profitability Trend

Net profit in Jenburkt Pharma Q1 FY27 results stood at Rs 5.00 Cr (-24.46% YoY). Near-term profitability moderation is being managed through cost optimisation initiatives.

Dividend Details

No dividend was announced along with Jenburkt Pharma Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.

FY27 Outlook for Jenburkt Pharma

Following Jenburkt Pharma Q1 FY27 results, management has reiterated its recovery roadmap, targeting operational efficiencies and revenue diversification to return to profitability. The pace of recovery in the Pharmaceuticals segment and macro tailwinds will be key monitorables. Investors tracking Jenburkt Pharma Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.

Jenburkt Pharma Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Jenburkt Pharma live price and get daily stock recommendations.

Jenburkt Pharma shares were trading lower at Rs 1135.65 (-2.03%) on August 6, 2026, following the declaration of Jenburkt Pharma Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 1135.65 on the results date, with a 52-week range reflecting the broader market sentiment toward the pharmaceuticals sector.

Key Risks for Jenburkt Pharma

Sector-Specific Headwinds

US FDA regulatory actions, pricing pressure in generics, and USFDA import alerts remain core risks.

Valuation and Earnings Risk

Sustained margin compression and earnings visibility remain key concerns for investors in the near term.

Operational and Financial Risk

Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.

Conclusion

Jenburkt Pharma Q1 FY27 results demonstrate pressure financial performance with revenue at Rs 35 Cr and PAT at Rs 5.00 Cr on a Standalone basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Jenburkt Pharma Q1 FY27 Results

When were Jenburkt Pharma Q1 FY27 results declared?

Ans. Jenburkt Pharma Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.

What was Jenburkt Pharma revenue in Q1 FY27?

Ans. Jenburkt Pharma Q1 FY27 results show revenue of Rs 35 Cr, -0.04% compared to Rs 35 Cr in Q1 FY26.

What was Jenburkt Pharma PAT in Q1 FY27?

Ans. Net profit (PAT) in Jenburkt Pharma Q1 FY27 results was Rs 5.00 Cr, -24.46% year-on-year.

Did Jenburkt Pharma declare a dividend in Q1 FY27?

Ans. No dividend was declared alongside Jenburkt Pharma Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.

What is the FY27 outlook for Jenburkt Pharma?

Ans. Jenburkt Pharma management has outlined a focus on operational restructuring and return to profitability for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.

How did the Jenburkt Pharma stock react to Q1 FY27 results?

Ans. Jenburkt Pharma shares were trading lower at Rs 1135.65 (-2.03%) on August 6, 2026, following the Jenburkt Pharma Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.